Response to Pazopanib-based Combination Regimen in a Case of FGFR3
Amplified Gastric Adenocarcinoma
- Sewanti Limaye,
- Darshana Patil,
- Dadasaheb Akolkar,
- Navin Srivastava,
- Revati Patil,
- Sachin Apurwa,
- Sanket Patil,
- Jinumary John,
- Rahul Gosavi,
- Prabhu Nesargikar,
- Prashant Kumar,
- Vineet Datta,
- Chirantan Bose,
- Zarrine Raazi,
- Ajay Srinivasan,
- Rajan Datar
Abstract
We report a case of an advanced refractory Gastric AD which responded
favourably to a combination regimen of AGI and other chemotherapy agents
which were selected on the basis of multi-analyte tumor profiling. The
treatment was well tolerated with transient manageable adverse events
and yielded radiological partial response.04 Aug 2021Submitted to Clinical Case Reports 06 Aug 2021Submission Checks Completed
06 Aug 2021Assigned to Editor
20 Aug 2021Reviewer(s) Assigned
25 Sep 2021Review(s) Completed, Editorial Evaluation Pending
25 Sep 2021Editorial Decision: Revise Minor
30 Sep 20211st Revision Received
01 Oct 2021Submission Checks Completed
01 Oct 2021Assigned to Editor
01 Oct 2021Review(s) Completed, Editorial Evaluation Pending
08 Oct 2021Editorial Decision: Accept
